Naproxen in the infectious season: antipyretic, anti-inflammatory, and potential antiviral effects Review article
Article Sidebar
Main Article Content
Abstract
The range of symptoms in viral infections varies from person to person. The most common symptoms include fever, sweating, fatigue, muscle and joint pain, and sometimes cough, weakness, or shortness of breath. These symptoms are often accompanied by progressive inflammation. Despite advances in pharmacotherapy, treatment for viral infections usually still relies on symptomatic therapy. In such cases, it is worth determining which medication will address all the symptoms reported by the patient and whether it also offers a direct inhibitory effect on viral growth and replication. According to a series of recent research findings, naproxen appears to offer precisely these possibilities. This paper presents the mechanism of naproxen’s comprehensive antipyretic, analgesic, and anti-inflammatory effects. It also describes the direct antiviral mechanisms of the drug, as demonstrated by scientific studies. They represent a promising direction for further research.
Article Details
Copyright by Medical Education. All rights reserved.
References
2. Coşkun Ö, Karakaş A, Savaşci Ü et al. The value of naproxen test as a diagnostic method to differentiate cause of fever. Taf Preventive Medicine Bulletin. 2012; 11: 779-82.
3. Kirshner JJ, McDonald MC 3rd, Kruter F et al. NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim. Support Care Cancer. 2018; 26(4): 1323-34. http://doi.org/10.1007/s00520-017-3959-2.
4. Kocot-Kępska M. Naproksen – multifunkcjonalny niesteroidowy lek przeciwzapalny. Lekarz POZ. 2020; 6(3): 215-20.
5. Sperber SJ, Hendley JO, Hayden FG et al. Effects of naproxen on experimental rhinovirus colds. A randomized, double-blind, controlled trial. Ann Intern Med. 1992; 117(1): 37-41. http://doi.org/10.7326/0003-4819-117-1-37.
6. Lejal N, Tarus B, Bouguyon E et al. Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus. Antimicrob Agents Chemother. 2013; 57(5): 2231-42. http://doi.org/10.1128/AAC.02335-12.
7. Clinical Trial: Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection (ENACOVID). https://clinicaltrials.gov/ct2/show/NCT04325633.
8. Valadan R, Alizadeh-Navaei R, Lagzian M et al. Repurposing naproxen as a potential nucleocapsid antagonist of beta-coronaviruses: targeting a conserved protein in the search for a broad-spectrum treatment option. J Biomol Struct Dyn. 2025; 43(13): 6700-15. http://doi.org/10.1080/07391102.2024.2321245.
9. Pawełczyk A, Nowak R, Gazecka M et al. Novel Molecular Consortia of Cannabidiol with Nonsteroidal Anti-Inflammatory Drugs Inhibit Emerging Coronaviruses’ Entry. Pathogens. 2023; 12(7): 951. http://doi.org/10.3390/pathogens12070951.
10. Dethleau N, Shalamova LA, Dias JS et al. Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus. Molecules. 2021; 26(9): 2593.
11. Hung IFN, To KKW, Chan JFW et al. Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial. Chest. 2017; 151(5): 1069-80. http://doi.org/10.1016/j.chest.2016.11.012.
12. Yousefifard M, Zali A, Zarghi A et al. Non-steroidal anti-inflammatory drugs in management of COVID-19; A systematic review on current evidence. Int J Clin Pract. 2020; 74(9): e13557. http://doi.org/10.1111/ijcp.13557.
13. Hui DSC, Chan KKP. Host Immunomodulatory Interventions in Severe Influenza. J Infect Dis. 2025; 232(Supplement 3): S262-72. http://doi.org/10.1093/infdis/jiaf328.
14. Kiani P, Dahl TA, Iversen JM et al. Efficacy of Naproxen/Fexofenadine (SJP-003) in the Prevention of Side Effects of Influenza Vaccination: Four Case Studies. Clin Pract. 2022; 12(5): 734-7. http://doi.org/10.3390/clinpract12050076.